-
Something wrong with this record ?
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
HP. Hartung, J. Mares, SG. Meuth, T. Berger
Language English Country United States
Document type Journal Article, Review
NLK
PubMed Central
from 2007
Europe PubMed Central
from 2007 to 1 year ago
ProQuest Central
from 2007-01-01 to 2023-10-31
Nursing & Allied Health Database (ProQuest)
from 2007-01-01 to 2023-10-31
Health & Medicine (ProQuest)
from 2007-01-01 to 2023-10-31
Psychology Database (ProQuest)
from 2007-01-01 to 2023-10-31
- MeSH
- Immunologic Factors administration & dosage MeSH
- Humans MeSH
- Drug Substitution methods MeSH
- Natalizumab administration & dosage adverse effects MeSH
- Observational Studies as Topic methods MeSH
- Leukoencephalopathy, Progressive Multifocal chemically induced immunology prevention & control MeSH
- Randomized Controlled Trials as Topic methods MeSH
- Risk Factors MeSH
- Multiple Sclerosis drug therapy immunology MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Brain and Mind Centre University of Sydney Sydney Australia
Department of Neurology Heinrich Heine University Düsseldorf Düsseldorf Germany
Department of Neurology Medical University of Vienna Vienna Austria
Department of Neurology Palacky University Olomouc Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012377
- 003
- CZ-PrNML
- 005
- 20220506130813.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13311-021-01102-w $2 doi
- 035 __
- $a (PubMed)34480292
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. hans-peter.hartung@uni-duesseldorf.de $u Brain and Mind Centre, University of Sydney, Sydney, Australia. hans-peter.hartung@uni-duesseldorf.de $u Department of Neurology, Palacky University, Olomouc, Olomouc, Czech Republic. hans-peter.hartung@uni-duesseldorf.de $u Department of Neurology, Medical University of Vienna, Vienna, Austria. hans-peter.hartung@uni-duesseldorf.de $1 https://orcid.org/0000000206146989 $7 nlk20050167624
- 245 10
- $a Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk / $c HP. Hartung, J. Mares, SG. Meuth, T. Berger
- 650 _2
- $a náhrada léků $x metody $7 D057915
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x aplikace a dávkování $7 D007155
- 650 _2
- $a progresivní multifokální leukoencefalopatie $x chemicky indukované $x imunologie $x prevence a kontrola $7 D007968
- 650 _2
- $a roztroušená skleróza $x farmakoterapie $x imunologie $7 D009103
- 650 _2
- $a natalizumab $x aplikace a dávkování $x škodlivé účinky $7 D000069442
- 650 _2
- $a pozorovací studie jako téma $x metody $7 D064887
- 650 _2
- $a randomizované kontrolované studie jako téma $x metody $7 D016032
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Mares, Jan $u Department of Neurology, Palacky University, Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Meuth, Sven G $u Department of Neurology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- 700 1_
- $a Berger, Thomas $u Department of Neurology, Medical University of Vienna, Vienna, Austria
- 773 0_
- $w MED00167290 $t Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics $x 1878-7479 $g Roč. 18, č. 3 (2021), s. 1654-1656
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34480292 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130805 $b ABA008
- 999 __
- $a ok $b bmc $g 1789812 $s 1163578
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 18 $c 3 $d 1654-1656 $e 20210903 $i 1878-7479 $m Neurotherapeutics $n Neurotherapeutics $x MED00167290
- LZP __
- $a Pubmed-20220425
